Drug intelligence / Profile preview

GW-TT3

Development stage: Preclinical
Lead developer: Gateway Biotechnology
Modality: Small Molecules

Overview

GW-TT3 is a small molecule new chemical entity (NCE) being developed by Gateway Biotechnology for the treatment of tinnitus. It is currently in the preclinical stage of development, with animal pharmacodynamic and pharmacokinetic studies underway to evaluate its efficacy and safety profile. Gateway Biotechnology, a company focused on hearing disorders, targets several cellular pathways including T-type calcium channels, inflammatory response pathways, and reactive oxygen/nitrogen species (ROS/RNS); however, the specific biological target and mechanism of action for GW-TT3 have not been publicly disclosed.

Beyond the preview

Go deeper on GW-TT3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GW-TT3.

Explore the full profile